Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
0.00 (0.00%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.24 - 10.85
Open     -
Vol / Avg. 0.00/389,813.00
Mkt cap 71.91M
P/E 5.04
Div/yield     -
EPS 0.29
Shares 49.59M
Beta 1.67
Inst. own 86%
Nov 3, 2016
Q3 2016 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Infinity Pharmaceuticals Inc Earnings Call
Aug 9, 2016
Q2 2016 Infinity Pharmaceuticals Inc Earnings Release
Jul 13, 2016
Infinity Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 559.74% -117.70%
Operating margin 560.30% -116.54%
EBITD margin - -114.44%
Return on average assets 99.37% -39.02%
Return on average equity 235.54% -83.35%
Employees 222 -
CDP Score - -


784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 51
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 61
Bio & Compensation  - Reuters
William C. Bertrand Jr. Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Sujay Kango Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Eric S. Lander Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters